Cargando…
The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up
Targeted therapies against human epidermal growth factor receptor 2 (HER2) are associated with increased interstitial lung disease (ILD). Trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended HER2 breast cancer survival but current knowledge on how these HER2-targeted...
Autores principales: | Chang, Chen-Han, Jung, Chiau-Jing, Huang, Yi-Ming, Chiao, Lo, Chang, Yih-Leong, Hsieh, Song-Chou, Lin, Ching-Hung, Kuo, Yu-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669110/ https://www.ncbi.nlm.nih.gov/pubmed/34894465 http://dx.doi.org/10.1016/j.breast.2021.11.016 |
Ejemplares similares
-
Tozinameran: Anti neutrophil cytoplasmic antibody-associated vasculitis: case report
Publicado: (2022) -
Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
por: Michailidou, Despina, et al.
Publicado: (2022) -
Azd-1222: Anti-Neutrophil Cytoplasmic Antibody-associated vasculitis: case report
Publicado: (2022) -
Tozinameran: Anti-neutrophil cytoplasmic antibody-associated vasculitis and massive rhabdomyolysis: case report
Publicado: (2021) -
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
por: Hellmark, Thomas, et al.
Publicado: (2019)